1. 1. ICH Q2 (R1) Validation of analytical procedures: text and methodology., International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. November 2005.
2. 2. Donald m., Jonathan H., and Majella E.: Rotigotine: A first chemical entity for transdermal drug delivery, Eur. J. Pharm. Biopharm.2014, (88) 586-593.
3. 3. Caslake R., Macleod A., Ives N., Stowe. R and Carl C.: monoamine B oxidase inhibitors versus other dopaminergic agents in early Parkinson's disease, Cochrane database of systematic reviews., 2009 (4).
4. 4. Francesc V., Antonio S., Jose.M, Jose Marey, Miguel M., and Angel A.: The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicenter, observational, retrospective, post marketing study, Int. J. Neurosci., 2017, 22:39.
5. 5. Shimon L., Simon H., Amnon H and Philip L.: Rasagiline-a novel MAO B inhibitor in parkinson's disease, Therapeutic and Risk management., 2007, 3(3) 467-474.